, Volume 53, Issue 2, pp 245–256

Recognition and Optimum Treatment of Brucellosis

  • Javier Solera
  • Elisa Martinez-Alfaro
  • Alfredo Espinosa
Disease Management


Brucellosis (infection with Bruceila spp.) is a common zoonosis in many parts of the world. Human brucellosis is a multisystem disease that may present with a broad spectrum of clinical manifestations. Treatment of brucellosis must effectively control acute illness and prevent complications and relapse. The choice of regimen and duration of antimicrobial therapy should be based on the presence of focal disease and underlying conditions which contraindicate certain specific antibiotics. The regimen of first choice is combination therapy with doxycycline for 45 days and streptomycin for 14 days. Gentamicin or netilmicin for the first 7 days may be substituted for streptomycin. Second-choice regimens consist of combinations of doxycycline and rifampicin (rifampin) for 45 days, or monotherapy with doxycycline for 45 days. Surgery should be considered for patients with endocarditis, cerebral or epidural abscess, spleen abscess or other abscesses which are antibiotic-resistant. Tetracyclines are generally contraindicated for pregnant patients and children <8 years old. Rifampicin 900mg once daily for 6 weeks is considered the drug of choice for treating brucellosis in pregnant women. In children <8 years old the preferred regimen is rifampicin with cotrimoxazole (trimethoprim-sulfamethoxazole) for 45 days. An alternative regimen consists of a combination of rifampicin for 45 days with gentamicin 5 to 6 mg/kg/day for the first 5 days.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mikolich DJ, Boyce JM. Bruceila species. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1990: 1735–42Google Scholar
  2. 2.
    Koneman EW, Allen SD, Janda WM, et al. Miscellaneous fastidious gram-negative bacilli. In: Koneman EW, Allen SD, Janda WM, et al., editors. Color atlas and textbook of diagnostic microbiology. 4th ed. Philadelphia: JB Lippincott, 1992: 303–49Google Scholar
  3. 3.
    Joint Food and Agriculture Organization/World Health Organization. FAO-WHO Expert Committee on Brucellosis (sixth report). WHO Technical Report Series No. 740. Geneva: World Health Organization, 1986: 56–7Google Scholar
  4. 4.
    Staszkiewicz J, Lewis CM, Colville J, et al. Outbreak of Brucella melitensis among microbiology laboratory workers in a community hospital. J Clin Microbiol 1991; 29: 287–90PubMedGoogle Scholar
  5. 5.
    Gruner E, Bernasconi E, Galeazzi RL, et al. Brucellosis: an occupational hazard for medical laboratory personnel. Report of five cases. Infection 1994; 22: 33–6PubMedCrossRefGoogle Scholar
  6. 6.
    Chusid MJ, Russler SK, Mohr BA, et al. Unsuspected brucellosis diagnosed in a child as a result of an outbreak of laboratory-acquired brucellosis. Pediatr Infect Dis J 1993; 12: 1031–3PubMedCrossRefGoogle Scholar
  7. 7.
    Martin-Mazuelos E, Nogales MC, Florez C, et al. Outbreak of Brucella melitensis among microbiology laboratory workers. J Clin Microbiol 1994; 32: 2035–6PubMedGoogle Scholar
  8. 8.
    Trout D, Gomez TM, Bernard BP, et al. Outbreak of brucellosis at a United States pork packing plant. J Occup Environ Med 1995; 37: 697–703PubMedCrossRefGoogle Scholar
  9. 9.
    Young EJ. Brucellosis outbreak attributed to ingestion of unpasteurized goat cheese. Arch Intern Med 1975; 135: 240–3PubMedCrossRefGoogle Scholar
  10. 10.
    Arnow PM, Smaron M, Ormists V. Brucellosis in a group of travellers to Spain. JAMA 1984; 251: 505–7PubMedCrossRefGoogle Scholar
  11. 11.
    Luzzi GA, Brindle R, Sockett PN, et al. Brucellosis: imported and laboratory-acquired cases, and an overview of treatment trials. Trans R Soc Trop Med Hyg 1993; 87: 138–41PubMedCrossRefGoogle Scholar
  12. 12.
    Chomel BB, DeBess EE, Mangiamele DM, et al. Changing trends in the epidemiology of human brucellosis in California from 1973 to 1992: a shift toward foodborne transmission. J Infect Dis 1994; 170: 1216–23PubMedCrossRefGoogle Scholar
  13. 13.
    Spink WW. Host-parasite relationship in brucellosis. Lancet 1964; II: 161–4CrossRefGoogle Scholar
  14. 14.
    Lulu AR, Araj GF, Khateeb MI. Human brucellosis in Kuwait: a prospective study of 400 cases. Q J Med 1988; 249: 39–54Google Scholar
  15. 15.
    Solera J, Medrano F, Rodrfguez M, et al. Ensayo terapéutico comparativo y multicéntrico de rifampicina y doxiciclina frente a estreptomicina y doxiciclina en la brucelosis humana. Med Clin 1991; 96: 649–53Google Scholar
  16. 16.
    Buchanan M, Faber LC, Fledman RA. Brucellosis in the United States 1960–1972: an abattoir associated disease. Part I: clinical features and therapy. Medicine 1974; 53: 403–13PubMedCrossRefGoogle Scholar
  17. 17.
    Centers for Disease Control and Prevention. Brucellosis out-break at a pork processing plant North Carolina, 1992. MMWR Morbid Mortal Wkly Rep 1994; 43: 113–6Google Scholar
  18. 18.
    Spink WW. The nature of brucellosis. Minneapolis: University of Minnesota Press, 1956Google Scholar
  19. 19.
    Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121: 953–9PubMedGoogle Scholar
  20. 20.
    Young EJ. An overview of human brucellosis. Clin Infect Dis 1995; 21: 283–90PubMedCrossRefGoogle Scholar
  21. 21.
    Hall WH. Modern chemotherapy for brucellosis in humans. Rev Infect Dis 1990; 12: 1060–99PubMedCrossRefGoogle Scholar
  22. 22.
    Solera J, Rodnguez-Zapata M, Geijo P, et al. Doxycyclinerifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. Antimicrob Agents Chemother 1995; 39: 2061–7PubMedCrossRefGoogle Scholar
  23. 23.
    Solera J, Espinosa A, Geijo P, et al. Treatment of human brucellosis with netilmicin and doxycycline. Clin Infect Dis 1996; 22: 441–5PubMedCrossRefGoogle Scholar
  24. 24.
    Ariza J, Corredoira J, Pallares R, et al. Characteristics of and risk factors for relapse of brucellosis in humans. Clin Infect Dis 1995; 20: 1241–9PubMedCrossRefGoogle Scholar
  25. 25.
    Crosby E, Llosa L, Miro Quesada M, et al. Hématologic changes in brucellosis. J Infect Dis 1984; 150: 419–24PubMedCrossRefGoogle Scholar
  26. 26.
    Di Mario A, Sica S, Zini G, et al. Microangiopathic hemolytic anemia and severe thrombocytopenia in Brucella infection. Ann Hematol 1995; 70: 59–60PubMedCrossRefGoogle Scholar
  27. 27.
    Gotuzzo E, Carrillo C, Guerra J, et al. An evaluation of diagnostic methods for brucellosis: the value of bone marrow culture. J Infect Dis 1986; 153: 122–5PubMedCrossRefGoogle Scholar
  28. 28.
    Gamazo C, Vitas AI, Lopez-Goñi I, et al. Factors affecting detection of Brucella melitensis by BACTEC NR73O, a nonradiometric system for hemocultures. J Clin Microbiol 1993; 31: 3200–3PubMedGoogle Scholar
  29. 29.
    Yagupsky P. Detection of Brucella melitensis by BACTEC NR660 blood culture system. J Clin Microbiol 1994; 32: 1899–901PubMedGoogle Scholar
  30. 30.
    Baldi PC, Miguel SE, Fossati CA, et al. Serological follow-up of human brucellosis by measuring IgG antibodies to lipopolysaccharide and cytoplasmic proteins of Brucella species. Clin Infect Dis 1996; 22: 446–55PubMedCrossRefGoogle Scholar
  31. 31.
    Alton GG, Jones LM, Pietz DE. Laboratory techniques in brucellosis. Geneva: World Health Organization, 1975Google Scholar
  32. 32.
    Romero C, Gamazo C, Pardo M, et al. Specific detection of Brucella DNA by PCR. J Clin Microbiol 1995; 33: 615–7PubMedGoogle Scholar
  33. 33.
    Leal-Klevezas DS, Martinez-Vazquez IO, Lopez-Merino A, et al. Single-step PCR for detection of Brucella spp. from blood and milk of infected animals. J Clin Microbiol 1995; 33: 3087–90PubMedGoogle Scholar
  34. 34.
    Matar GM, Khneisser IA, Abdelnoor AM. Rapid laboratory confirmation of human brucellosis by PCR analysis of target sequence on the 31-kilodalton Brucella antigen DNA. J Clin Microbiol 1996; 34: 477–8PubMedGoogle Scholar
  35. 35.
    Gutiérrez Altés A, Diez M, Peña P, et al. In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampicin, tetracycline and cotrimoxazole. Antimicrob Agents Chemother 1982; 21: 501–3PubMedCrossRefGoogle Scholar
  36. 36.
    Mortensen JE, Moore DG, Clarridge JE, et al. Antimicrobial susceptibility of clinical isolates of brucella. Diagn Microbiol Infect Dis 1986; 5: 163–9PubMedCrossRefGoogle Scholar
  37. 37.
    Qadri SM, al-Sedairy S, Ueno Y. Antibacterial activity of lomefloxacin against Brucella melitensis. Diagn Microbiol Infect Dis 1990; 13: 277–9PubMedCrossRefGoogle Scholar
  38. 38.
    Magill GB, Killough JH. Oxytetracycline-streptomycin therapy in brucellosis due to Brucella melitensis. Arch Intern Med 1953; 91: 204–11CrossRefGoogle Scholar
  39. 39.
    Feiz JM, Sabbaghian H, Sohrabi F. A comparative study of therapeutic agents used for treatment of acute brucellosis. Br J Clin Pract 1973; 27: 410–3PubMedGoogle Scholar
  40. 40.
    Montejo JM, Alberola I, González-Zarate P, et al. Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis. Clin Infect Dis 1993; 16: 671–6PubMedCrossRefGoogle Scholar
  41. 41.
    Rubinstein E, Lang R, Shasha B, et al. In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother 1991; 35: 1925–7PubMedCrossRefGoogle Scholar
  42. 42.
    Richardson M, Holt JN. Synergistic action of streptomycin with other antibiotics on intracellular Brucella abortus in vitro. J Bacteriol 1962; 84: 638–46PubMedGoogle Scholar
  43. 43.
    Ariza J, Gudiol F, Pallarés R, et al. Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis. Antimicrob Agents Chemother 1985; 28: 548–51PubMedCrossRefGoogle Scholar
  44. 44.
    Ariza J, Gudiol F, Pallarés R, et al. Comparative trial of cotrimoxazole versus tetracycline-streptomycin in treating human brucellosis. J Infect Dis 1985; 152: 1358–9PubMedCrossRefGoogle Scholar
  45. 45.
    Rodrfguez Zapata M, Gamo Herranz A, de la Morena Fernández J. Comparative study of two regimens in the treatment of brucellosis. Chemioterapia 1987; 6 (2 Suppl.): 360–2Google Scholar
  46. 46.
    Colmenero Castillo JD, Hernandez Marquez S, Reguera Iglesias JM, et al. Comparative trial of doxycycline plus streptomycin versus doxycycline plus rifampin for the therapy of human brucellosis. Chemotherapy 1989; 35: 146–52PubMedCrossRefGoogle Scholar
  47. 47.
    Cisneros JM, Viciana P, Colmenero J, et al. Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks and streptomycin for 2 weeks. Antimicrob Agents Chemother 1990; 34: 881–3PubMedCrossRefGoogle Scholar
  48. 48.
    Ariza J, Gudiol F, Pallares R, et al. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin: a randomized, double-blind study. Ann Intern Med 1992; 117: 25–30PubMedGoogle Scholar
  49. 49.
    Acocella G, Bertrand A, Beytout J, et al. Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study. J Antimicrob Chemother 1989; 23: 433–9PubMedCrossRefGoogle Scholar
  50. 50.
    Lubani MM, Dubin KI, Sharda DC, et al. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr Infect Dis J 1989; 8: 75–8PubMedCrossRefGoogle Scholar
  51. 51.
    Llorens-Terol J, Busquets RM. Brucellosis treated with rifampin. Arch Dis Child 1980; 55: 486–8PubMedCrossRefGoogle Scholar
  52. 52.
    Bertrand A, Roux J, Janbon F, et al. Traitement de la brucellose par la rifampicine: résultats préliminaires. Nouv Press Med 1979; 8: 3635–9Google Scholar
  53. 53.
    Godeau P, Fuchs G, Guillevin L, et al. Traitement de la brucellose humaine par la rifampicine. Sem Hop 1984; 60: 5–9PubMedGoogle Scholar
  54. 54.
    Solera J, Martinez-Alfaro E, Saez L, et al. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin: a meta-analysis of randomized controlled trials (abstract no. M74]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 4–7 Oct 1994; Orlando. Washington, DC: American Society for Microbiology, 1994: 261Google Scholar
  55. 55.
    Colmenero JD, Fernández-Gallardo LC, Agundez J A, et al. Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. Antimicrob Agents Chemother 1994; 38: 2798–802PubMedCrossRefGoogle Scholar
  56. 56.
    Robersont L, Farrell ID, Hinchliffe PM. The sensitivity of Brucella abortus to chemotherapeutic agents. J Med Microbiol 1973; 6: 549–57CrossRefGoogle Scholar
  57. 57.
    Lal S, Modawal KK, Fowle ASE, et al. Acute brucellosis treated with trimethoprim and sulphametoxazole. BMJ 1970; 3: 256–7PubMedCrossRefGoogle Scholar
  58. 58.
    Hassan A, Erian MM, Farid Z, et al. Trimethoprim-sulphametoxazole in acute brucellosis. BMJ 1971; 3: 159–60PubMedCrossRefGoogle Scholar
  59. 59.
    Daikos GK, Papapolyzos N, Marketos N, et al. Trimethoprim-sulphametoxazole in brucellosis. J Infect Dis 1973; 128 Suppl.: S731–3CrossRefGoogle Scholar
  60. 60.
    Khan MY, Dizon M, Kiel FW. Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Bruceila melitensis. Antimicrob Agents Chemother 1989; 33: 1409–10PubMedCrossRefGoogle Scholar
  61. 61.
    Lang R, Rubinstein E. Quinolones for the treatment of brucellosis. J Antimicrob Chemother 1992; 29: 357–60PubMedCrossRefGoogle Scholar
  62. 62.
    Al-Sibai MB, Halim MA, el-Shaker MM, et al. Efficacy of ciprofloxacin for treatment of Brucella melitensis infections. Antimicrob Agents Chemother 1992; 36: 150–2PubMedCrossRefGoogle Scholar
  63. 63.
    Lang R, Raz R, Sacks T, et al. Failure of prolonged treatment with ciprofloxacin in acute infections due to Bruceila melitensis. J Antimicrob Chemother 1990; 26: 841–6PubMedCrossRefGoogle Scholar
  64. 64.
    Garcia Rodríguez JA, Garcia Sánchez JE, Trujillano I. Lack of effective bactericidal activity of new quinolones against Brucella sp. Antimicrobial Agents Chemother 1991; 35: 756–8CrossRefGoogle Scholar
  65. 65.
    Akova M, Uzun O, Akalin HE, et al. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993; 37: 1831–4PubMedCrossRefGoogle Scholar
  66. 66.
    Landínez R, Linares J, Loza E, et al. In vitro activity of azithromycin and tetracycline against 358 clinical isolates of Bruceila melitensis. Eur J Clin Microbiol Infect Dis 1992; 11: 265–7PubMedCrossRefGoogle Scholar
  67. 67.
    García-Rodríguez JA, Muñoz Bellido JL, Fresnadillo MJ, et al. In vitro activities of new macrolides and rifapentine against Bruceila spp. Antimicrob Agents Chemother 1993; 37: 911–3PubMedCrossRefGoogle Scholar
  68. 68.
    Qadri SM, Halim MA, Ueno Y, et al. Antibacterial activity of azithromycin against Bruceila melitensis. Chemotherapy 1995; 41: 253–6PubMedCrossRefGoogle Scholar
  69. 69.
    Dunn CJ, Barradell LB. Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996 Mar; 51(3): 483–505PubMedCrossRefGoogle Scholar
  70. 70.
    Lang R, Shasha B, Ifrach N, et al. Therapeutic effects of roxythromycin and azithromycin in experimental murine brucellosis. Chemotherapy 1994; 40: 252–5PubMedCrossRefGoogle Scholar
  71. 71.
    Domingo S, Idoya Gastearena I, Vitas AI, et al. Comparative activity of azithromycin and doxycycline against Brucella spp. infection in mice. J Antimicrob Chemother 1995; 36: 647–56PubMedCrossRefGoogle Scholar
  72. 72.
    Fountain MW, Weis SJ, Fountain AG, et al. Treatment of Brucella camis and Brucella abortus in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides. J Infect Dis 1985; 152: 529–35PubMedCrossRefGoogle Scholar
  73. 73.
    Hernandez-Caselles T, Vera A, Crespo F, et al. Treatment of Brucella melitensis infection in mice by use of liposome-encapsulated gentamicin. Am J Vet Res 1989; 50: 1486–8PubMedGoogle Scholar
  74. 74.
    Lifeso RM, Harder E, McCorkell SJ. Spinal brucellosis. J Bone Joint Surg Br 1985; 67-B: 345–51Google Scholar
  75. 75.
    Vallejo JG, Stevents AM, Dutton RV, et al. Hepatosplenic abscesses due to Brucella melitensis: report of a case involving a child and review of the literature. Clin Infect Dis 1996; 22: 485–9PubMedCrossRefGoogle Scholar
  76. 76.
    Fernández-Guerrero M. Zoonotic endocarditis. Infect Dis Clin North Amer 1993; 7: 135–52Google Scholar
  77. 77.
    Al-Harthi SS. The morbidity and mortality pattern of Brucella endocarditis. Int J Cardiol 1989; 25: 321–4PubMedCrossRefGoogle Scholar
  78. 78.
    Jacobs F, Abramowicz D, Vereerstraeten P, et al. Brucella endocarditis: the role of combined medical and surgical treatment. Rev Infect Dis 1990; 12: 740–4PubMedCrossRefGoogle Scholar
  79. 79.
    Al-Kasab S, Al-Fagih MR, Al-Yousef S, et al. Brucella infective endocarditis: successful combined medical and surgical therapy. J Thorac Cardiovasc Surg 1988; 95: 862–7PubMedGoogle Scholar
  80. 80.
    Fernández Guerrero ML, Martinell J, Aguado JM, et al. Prosthetic valve endocarditis caused by Brucella melitensis. Arch Intern Med 1987; 147: 1141–4PubMedCrossRefGoogle Scholar
  81. 81.
    Delvecchio G, Fracassetti O, Lorenzi N. Brucella endocarditis. Int J Cardiol 1991; 33: 28–9CrossRefGoogle Scholar
  82. 82.
    McLean DR, Russell N, Khan MY. Neurobrucellosis: clinical and therapeutic features. Clin Infect Dis 1992; 15: 582–90PubMedCrossRefGoogle Scholar
  83. 83.
    Bouza E, Garcia de la Torre M, Parras F, et al. Brucellar meningitis. Rev Infect Dis 1987; 9: 810–22PubMedCrossRefGoogle Scholar
  84. 84.
    Shakir RA, Al-Din ASN, Araj GF, et al. Clinical categories of neurobrucellosis. Brain 1987; 110: 213–23PubMedCrossRefGoogle Scholar
  85. 85.
    Al-Deeb SM, Yaqub BA, Sharif HS, et al. Neurobrucellosis: clinical characteristics, diagnosis, and outcome. Neurology 1989; 39: 498–501PubMedCrossRefGoogle Scholar
  86. 86.
    Khuri-Bulos NA, Daoud AH, Azab SM. Treatment of childhood brucellosis: results of a prospective trial on 113 children. Pediatr Infect Dis 1993; 12: 377–81CrossRefGoogle Scholar
  87. 87.
    Madkour MM. Treatment. In: Madkour MM, editor. Brucellosis. London: Butterworths, 1989: 219–43Google Scholar
  88. 88.
    Gómez-Reino FJ, Mateo I, Fuertes A, et al. Brucellar arthritis in children and its successful treatment with trimethoprim-sulphamethoxazole (co-trimoxazole). Ann Rheum Dis 1986; 45: 256–8PubMedCrossRefGoogle Scholar
  89. 89.
    Gotuzzo E, Carrillo C. Brucella. In: Gorbach SL, Bartlett JH, Blacklow NR, editors. Infectious diseases. Philadelphia: Saunders, 1992; 1513–21Google Scholar
  90. 90.
    Figueroa Damian R, Rojas Rodriguez L, Marcano Tochon ES. Brucelosis durante el embarazo: evolucion y resultados perinatales. Ginecol Obstet Mex 1995; 63: 190–5PubMedGoogle Scholar
  91. 91.
    Korzeniowski OM. Antibacterial agents in pregnancy. Infect Dis Clin North America 1995; 9: 639–51Google Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Javier Solera
    • 1
  • Elisa Martinez-Alfaro
    • 1
  • Alfredo Espinosa
    • 1
  1. 1.Department of Medicine, Unit of Infectious DiseasesAlbacete General HospitalAlbaceteSpain

Personalised recommendations